Food Allergy Market Insights, Epidemiology, and Market Forecast-2030

Food Allergy Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight Business Research LLP
DelveInsight’s ‘Food Allergy Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Food Allergy (FA), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Food Allergy Market

The Food Allergy market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted FA symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Food Allergy (FA) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Food Allergy (FA) Market Outlook

The Food Allergy market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Food Allergy (FA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Food Allergy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key Findings

This section includes a glimpse of the Food Allergy (FA) market in 7MM. The market size of FA in the seven major markets was found to be USD 1,091 million in 2020.

The United States Market Outlook

This section provides a total of Food Allergy (FA) market size and market size by therapies in the United States.

The United States accounts for the highest FA market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Food Allergy (FA) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Food Allergy (FA) market size and market size by therapies in Japan are also mentioned.

Scope of the Report

  • The report covers the descriptive overview of Food Allergy (FA) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Food Allergy (FA) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Food Allergy (FA) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Food Allergy (FA) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Food Allergy (FA) market

Request for sample pages @ Food Allergy Market Size 

Table of contents

1. Key Insights

2. Report Introduction

3. Food Allergy (FA) Market Overview at a Glance

3.1. Market Share (%) Distribution of Food allergy in 2018

3.2. Market Share (%) Distribution of Food allergy in 2030

4. Executive Summary of Food allergy

5. Organizations contributing towards Food Allergy (FA)

6. Disease Background and Overview

6.1. Introduction

6.2. Etiology

6.3. Clinical Manifestations

6.4. Subtypes of Food Allergy

6.5. Diagnosis

7. Management and Treatment

7.1. Guidelines

7.2. Japanese Guidelines for Food allergies

7.2.1. Symptom Severity and Treatment

7.2.1.1. Grading symptom severity

7.2.1.2. Treatment based on symptom severity

7.2.1.3. Evaluation of organ-specific symptoms

7.2.2. Management of Anaphylaxis in a Health Care Setting

7.2.2.1. Confirmation of vital signs

7.2.2.2. Ensuring staff and treatment by a team

7.2.2.3. Intramuscular injection of adrenaline

7.2.2.4. Body position of the anaphylaxis patients

7.2.2.5. Administration of oxygen

7.2.2.6. Securing the intravenous infusion route and rapid rehydration

7.2.2.7. Cessation of respiration

7.2.2.8. Measurement of vital signs: Re-evaluation

7.2.3. Contraindication of adrenaline

7.3. The European Academy of Allergy and Clinical Immunology (EAACI) Guidelines

7.4. American Guidelines for the Diagnosis and Management of Food allergies

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. 7MM Total Prevalent Patient Population of Food Allergy (FA)

8.3. Assumption and Rationale

8.4. The United States

8.4.1. Prevalent cases of Food Allergy (FA) in the United States

8.4.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in the United States

8.4.3. Age-specific Prevalence of Food Allergy (FA) in the United States

8.5. EU5

8.5.1. Germany

8.5.1.1. Prevalent cases of Food Allergy (FA) in Germany

8.5.1.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Germany

8.5.1.3. Age-specific Prevalence of Food Allergy (FA) in Germany

8.5.2. France

8.5.2.1. Prevalent cases of Food Allergy (FA) in France

8.5.2.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in France

8.5.2.3. Age-specific Prevalence of Food Allergy (FA) in France

8.5.3. Italy

8.5.3.1. Prevalent cases of Food Allergy (FA) in Italy

8.5.3.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Italy

8.5.3.3. Age-specific Prevalence of Food Allergy (FA) in Italy

8.5.4. Spain

8.5.4.1. Prevalent cases of Food Allergy (FA) in Spain

8.5.4.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Spain

8.5.4.3. Age-specific Prevalence of Food allergy in Spain

8.5.5. United Kingdom

8.5.5.1. Prevalent cases of Food Allergy (FA) in the United Kingdom

8.5.5.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in the United Kingdom

8.5.5.3. Age-specific Prevalence of Food Allergy (FA) in the United Kingdom

8.6. Japan

8.6.1. Prevalent cases of Food Allergy (FA) in Japan

8.6.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Japan

8.6.3. Age-specific Prevalence of Food Allergy (FA) in Japan

9. Patient Journey

10. Case Reports

11. Marketed Therapies

11.1. Palforzia: Aimmune Therapeutics, Inc.

11.1.1. Drug Description

11.1.2. Other Development Information

11.1.3. Safety and Efficacy

11.1.4. Product Profile

12. Emerging Therapies

12.1. Ligelizumab: Novartis Pharmaceuticals

12.1.1. Drug Descriptions

12.1.2. Clinical Development

12.1.3. Clinical Trials Information

12.1.4. Product Profile

12.2. Viaskin Peanut: DBV Technologies

12.2.1. Drug Descriptions

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Clinical Trials Information

12.2.5. Product Profile

12.3. INP20: InnoUp Farma S.L.

12.3.1. Drug Descriptions

12.3.2. Clinical Development

12.3.3. Clinical Trials Information

12.3.4. Safety and Efficacy

12.3.5. Product Profile

12.4. CNP-201: COUR Pharmaceutical Development Company Inc.

12.4.1. Drug Descriptions

12.4.2. Clinical Development

12.4.3. Clinical Trials Information

12.4.4. Product Profile

12.5. VE416: Vedanta Biosciences, Inc.

12.5.1. Drug Descriptions

12.5.2. Clinical Development

12.5.3. Clinical Trials Information

12.5.4. Product Profile

12.6. AR201: Aimmune Therapeutics, Inc.

12.6.1. Drug Descriptions

12.6.2. Other Developmental Activities

12.6.3. Clinical Development

12.6.4. Clinical Trials Information

12.6.5. Safety and Efficacy

12.6.6. Product Profile

12.7. Dupilumab: Regeneron Pharmaceuticals

12.7.1. Drug Descriptions

12.7.2. Other Developmental Activities

12.7.3. Clinical Development

12.7.4. Clinical Trials Information

12.7.5. Product Profile

12.8. Omalizumab: Genentech, Inc. /Novartis Pharmaceuticals

12.8.1. Drug Descriptions

12.8.2. Other Development Information

12.8.3. Clinical Development

12.8.4. Clinical Trials Information

12.8.5. Safety and Efficacy

12.8.6. Product Profile

12.9. CA002: Camallergy

12.9.1. Drug Description

12.9.2. Other development activity

12.9.3. Clinical Development

12.9.4. Clinical Trials Information

12.9.5. Safety and Efficacy

12.9.6. Product profile

13. Food allergy: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Size of Food allergy in 7MM

13.3. Market Size of Food allergy by Therapies

14. Market Outlook

14.1. United States Market Size

14.1.1. Total Market Size of Food Allergy (FA) in the United States

14.1.2. Market Size of Food Allergy (FA) by Therapies in the United States

14.2. EU-5 Market Size

14.2.1. Germany

14.2.1.1. Total Market size of Food Allergy (FA) in Germany

14.2.1.2. Market Size of Food Allergy (FA) by Therapies in Germany

14.2.2. France

14.2.2.1. Total Market size of Food Allergy (FA) in France

14.2.2.2. Market Size of Food Allergy (FA) by Therapies in France

14.2.3. Italy

14.2.3.1. Total Market size of Food Allergy (FA) in Italy

14.2.3.2. Market Size of Food Allergy (FA) by Therapies in Italy

14.2.4. Spain

14.2.4.1. Total Market size of Food Allergy (FA) in Spain

14.2.4.2. Market Size of Food Allergy (FA) by Therapies in Spain

14.2.5. United Kingdom

14.2.5.1. Total Market size of Food Allergy (FA) in United Kindgom

14.2.5.2. Market Size of Food Allergy (FA) by Therapies in United Kingdom

14.3. Japan

14.3.1. Total Market size of Food Allergy (FA) in Japan

14.3.2. Market Size of Food Allergy (FA) by Therapies in Japan

15. KOL Views

16. Unmet Needs

17. Market Drivers

18. Market Barriers

19. SWOT Analysis

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/